SE, happy to hear from you.
I gave the chart a second look wanting to expand the use of the medication. Only looking at CTX/P1NP ratios (which do correspond with bone acquisition after 12 months) may be short sighted, if osteoblasts live a few weeks or months and osteocytes live for decades.
There may be a cycle (beyond the daily/nightly) where the balance of CTX/P1NP needs to be imbalanced for more effective bone growth.
I worry (a little)because personally I have noticed that three weeks of not taking the medication drops the CTX in greater percentage than P1NP. In taking advantage of that shift in balance, I might be disrupting a larger uncharted process, rather than my hope of expanding the anabolic window.
I'm searching for references regarding the 10 to 1. Without positing any hypothesis, I like my osteoblast number close to the osteoclast number, valuing those much maligned osteoclasts.
I'd love to see your bone marker numbers. Good for getting them from the Rheumatologist.
You may not care enough about the canaliculus, but here is Ebreheim.

I must have read a speculation about the lowering of bone density in the hip with the anabolics. Then it made personal sense to me that porosity can increase flexibility and lessen fracture risk.
Have you decided on an antiresorptive.